Integration of monoclonal antibodies and immunoconjugates into the treatment of acute myeloid leukemia
Authors:
- Sergio AmadoriSASergio Amadori
- Roberto StasiRSRoberto Stasi
- 1 March 2008
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Hematology
- Vol. 15 (2) , 95-100
Abstract
This review addresses use of monoclonal antibodies and immunoconjugates to treat acute myeloid leukemia. Monoclonal antibodies used in acute myeloid leukemia have been directed against the antigens CD33, CD45, and CD66. Unconjugated monoclonal antibodies such as lintuzumab have modest activity against overt acute myeloid leukemia but can eliminate minimal residual disease in acute promyelocytic leukemia. Most experience with immunoconjugates is with gemtuzumab ozogamicin, an anti-CD33 monoclonal antibody linked to the potent antitumor antibiotic calicheamicin. Gemtuzumab ozogamicin has shown activity both singly, particularly in acute promyelocytic leukemia, and combined with conventional cytotoxic chemotherapy. Radiolabeled monoclonal antibodies against CD45 and CD66 have also been used to intensify the conditioning regimen before stem cell transplantation. The most promising results were obtained with radiolabeled anti-CD45 antibodies. Antibodies reactive with CD66 have been used to deliver targeted radiation to hematopoietic tissues in patients with advanced myeloid malignancies. Both unlabeled monoclonal antibodies and immunoconjugates appear to have a limited role if used as single agents to treat acute myeloid leukemia. These agents hold promise as potentially useful additions to conventional therapy, but the optimal dosing and timing remain to be defined.Keywords
This publication has 44 references indexed in Scilit:
- Monoclonal antibodies and immunoconjugates in acute myeloid leukemiaBest Practice & Research Clinical Haematology, 2006
- Phase III Randomized Multicenter Study of a Humanized Anti-CD33 Monoclonal Antibody, Lintuzumab, in Combination With Chemotherapy, Versus Chemotherapy Alone in Patients With Refractory or First-Relapsed Acute Myeloid LeukemiaJournal of Clinical Oncology, 2005
- Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin–induced cytotoxicityBlood, 2005
- CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistanceLeukemia, 2004
- Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemiasBone Marrow Transplantation, 2003
- Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195Leukemia, 2003
- Gemtuzumab Ozogamicin, A Potent and Selective Anti-CD33 Antibody−Calicheamicin Conjugate for Treatment of Acute Myeloid LeukemiaBioconjugate Chemistry, 2001
- Antibody therapy for residual disease in acute myelogenous leukemiaCritical Reviews in Oncology/Hematology, 2001
- Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugateLeukemia, 2000
- A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicityBlood, 1994